Prevention of diabetic eye disease: The commonest cause of blindness in individuals younger than 65 years

Clinical Ophthalmology

Volumn 4, Issue 1, 2010, Pages 1291-1298

  Tatti, Patrizio ^a   di Mauro, Patrizia ^a   Masselli, Leonardo ^a   Longobardi, Adriano ^a   Barber, Annabel ^b  

^a Ospedale S Giuseppe   (Italy)

^b UNIVERSITY OF NEVADA   (United States)

Author keywords

Blindness; Diabetes; Eye disease; Prevention

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMINOGUANIDINE; BEVACIZUMAB; CANDESARTAN; FENOFIBRATE; GROWTH HORMONE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LISINOPRIL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OCTREOTIDE; PEGAPTANIB; PEGVISOMANT; PROTEIN KINASE C; RANIBIZUMAB; SOMATOMEDIN C; VASCULOTROPIN;

ARTICLE; BLINDNESS; DIABETIC MACULAR EDEMA; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE DURATION; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOGENESIS; PREVALENCE; RETINA NEOVASCULARIZATION; SCREENING;

EID: 78650685925     PISSN: 11775467     EISSN: 11775483     Source Type: Book Series    
DOI: 10.2147/OPTH.S10273     Document Type: Article

References (71)

1. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The Wisconsin epidemiologic study; Part III: prevalence and risk of diabetic retinopathy when age at diagnosis is thirty or more years. Arch Ophthalmol. 1984; 102:527-533.
2. Kohener EM, Stratton IM, Aldinton SJ. Prevalence of diabetic retinopathy at diagnosis of NIDDM in the UKPDS. Invest Ophthalmol Vis Sci. 1993;34:713.
3. Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the US: 1990-1998. Diabetes Care. 2000;23:1278-1283.
4. Foulds WS, MacCuish AC, Barrie T. The cost effectiveness of screening for diabetic retinopathy. Semin Ophthalmol. 1987;2:45-50.
5. Scobie IN, MacCuish AC, Green FD, Foulds WS. Serious retinopathy in a diabetic clinic: prevalence and therapeutic implications. Lancet. 1981;2:520-521.
6. Garg S, Davis RM. Diabetic retinopathy screening update. Clin Diabetes. 2009;27:140-145.
7. Barber AJ. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27:283-290.
8. Antonelli-Orlidge A, Smith SR, D'Amore PA. Influence of pericytes on capillary endothelial cell growth. Am Rev Respir Dis. 1989;140: 1129-1131.
9. Speiser P, Gittelsohn AM, Patz A. Studies on diabetic retinopathy; Part III: influence of diabetes on intramural pericytes. Arch Ophthalmol. 1968;80:332-337.
10. Mogensen CE, Osterby R, Gundersen HJ. Early functional and morphologic vascular renal consequences of the diabetic state. Diabetologia. 1979;17:71-76.
11. Miyamoto K, Ogura Y. Pathogenetic potential of leukocytes in diabetic retinopathy. Semin Ophthalmol. 1999;14:233-239.
12. Rand LI, Krolewski AS, Aiello LM, Warram JH, Baker RS, Maki T. Multiple factors in the prediction of risk of proliferative diabetic retinopathy. N Engl J Med. 1985;313:1433-1437.
13. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
14. Knowler WC, Bennett PH, Ballintine EJ. Increased incidence of retinopathy in diabetics with elevated blood pressure. N Engl J Med. 1980;302:645-650.
15. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. Is blood pressure a predictor of the incidence and progression of diabetic retinopathy? Arch Intern Med. 1989;149:2427-2432.
16. Moloney JB, Drury MI. The effect of pregnancy on the natural course of diabetic retinopathy. Am J Ophthalmol. 1982;93:745-756.
17. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care. 1990;13:34-40.
18. Dorchy H. Screening for subclinical diabetic complications in young type 1 diabetic patients: experience acquired in Brussels. Pediatr Endocrinol Rev. 2004;1:380-403.
19. Aiello LP, Cahill MT, Wong JS. Systemic considerations in the management of diabetic retinopathy. Am J Ophthalmol. 2001;132:760-776.
20. Klein BE, Moss SE, Klein R, Surawicz TS. Serum cholesterol in the Wisconsin epidemiologic study of diabetic retinopathy. Diabetes Care. 1992;15:282-287.
21. Leung H, Wang JJ, Rochtchina E, Wong TY, Klein R, Mitchell P. Dyslipidaemia and microvascular disease in the retina. Eye (Lond). 2005;19:861-868.
22. Brown JB, Pedula KL, Summers KH. Diabetic retinopathy. Diabetes Care. 2003;26:2637-2642.
23. Retinopathy and nephropathy in patients with type I diabetes four years after a trail of intensive therapy. The Diabetes Control and Complications Trial/Epidemiology of Diabetes and Complications Research Group. N Engl J Med. 2000;342:381-389.
24. Yiling J, Cheng J. Association of A1C and fasting plasma glucose levels with diabetic retinopathy prevalence in the US population. Diabetes Care. 2009;32:2027-2032.
25. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-853.
26. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
27. Duckworth W, Abraira C, Moritz T, et al; VADT Investigators. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
28. Patel A, MacMahon S, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
29. Obrosova IG, Minchenko AG, Vasupuram R, et al. Aldose reductase inhibitor fidalrestat prevents retinal oxidative stress and vascular endothelial growth factor overexpression in streptozotocin diabetic rats. Diabetes. 2003;52:864-871.
30. Abhary S, Burdon KP, Laurie KJ, et al. Aldose reductase gene polymorphisms and diabetic retinopathy susceptibility. Diabetes Care. 2010;33:1834-1836.
31. Obrosova IG, van Huysen C, Fathallah L, Cao XC, Greene DA, Stevens MJ. An aldose reductase inhibitor reverses early diabetes- induced changes in peripheral nerve function, metabolism and antioxidative defense. FASEB J. 2002;16:123-125.
32. Petrovic MG, Peterlin B, Hawlina M, Petrovic D. Aldose reductase (AC)n gene polymorphism and susceptibility to diabetic retinopathy in type 2 diabetes in Caucasians. J Diabetes Complications. 2005;19: 70-73.
33. Tromp A, Hooymans JM, Barendsen BC, van Doormaal JJ. The effects of an aldose reductase inhibitor on the progression of diabetic retinopathy. Doc Ophthalmol. 1991;78:153-159.
34. van Gerven JM, Boot JP, Lemkes HH, van Best JA. Effects of aldose reductase inhibition with tolrestat on diabetic retinopathy in a six months double blind trial. Doc Ophthalmol. 1994;87:355-365.
35. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a causal antioxidant therapy. Diabetes Care. 2003;26: 1589-1596.
36. Giugliano D, Marfella R, Coppola L, et al. Vascular effects of acute hyperglycemia in humans are reversed by L-arginine: evidence for reduced availability of nitric oxide during hyperglycemia. Circulation. 1997;95:1783-1790.
37. Nishikawa T, Brownlee M. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787-790.
38. Collins T. Endothelial nuclear factor kB and the initiation of the atherosclerotic lesion. Lab Invest. 1993;68:499-508.
39. Marchioli R, Schweiger C, Levantesi G, Tavazzi L, Valagussa F. Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data. Lipids. 2001;36:S53-S63.
40. Cuzzocrea S. Antioxidant therapy: a new pharmacological approach in shock, inflammation, and ischemia /reperfusion injury. Pharmacol Rev. 2001;53:135-159.
41. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab. 2001;27: 535-542.
42. Stitt AW, Bhaduri T, McMullen CB, Gardiner TA, Archer DB. Advanced glycation end products induce blood-retinal barrier dysfunction in normoglycemic rat. Mol Cell Biol Res Commun. 2000;3: 380-388.
43. Mamputu JC, Renier G. Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. J Leukoc Biol. 2004;75:1062-1069.
44. Zhang Q, Zhang J, Guan Y, et al. Suppression of retinal neovascularization by the iNOS inhibitor aminoguanidine in mice of oxygeninduced retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247: 919-927.
45. Danis RP, Bingaman DP, Jirousek M, Yang Y. Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531. Invest Ophthalmol Vis Sci. 1998;39: 171-179.
46. Ways DK, Sheetz MJ. The role of protein kinase C in the development of the complications of diabetes. Vitam Horm. 2000;60:149-193.
47. Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol. 1993;265:E783-E793.
48. Aiello LP, Davis MD, et al; PKC-DRS2 Group. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006;113:2221-2230.
49. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005;54:1615-1625.
50. Hetizer T, Finckh B, Albers S, Krohn K, Kohlschütter A, Meinertz T. Beneficial effects of alpha-lipoic acid and ascorbic acid on endothelium- dependent, nitric oxidemediated vasodilation in diabetic patients relation to parameters of oxidative stress. Free Radic Biol Med. 2001;31:53-61.
51. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
52. Simó R, Hernandez C. Intravitreous antiVEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy. Diabetologia. 2008;51: 1574-1580.
53. Wirostko B, Wong TY, Simó R. Vascular endothelial growth factor and diabetic complications. Prog Retin Eye Res. 2008;27:608-621.
54. Sharp PS, Fallon TJ, Brazier OJ, Sandler L, Joplin GF, Kohner EM. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia. 1987;30:199-207.
55. Chantelau E. Evidence that upregulation of serum IGF-1 concentration causes acceleration of diabetic retinopathy. Br J Ophthalmol. 1998;82: 725-730.
56. Growth Hormone Antagonist for Proliferative Diabetic Retinopathy Study Group. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology. 2001;108: 2266-2272.
57. Grant MB, Mames RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care. 2000;23: 504-509.
58. Chew EY, et al; ACCORD Study Group, ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363:233-234.
59. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Br Med J. 1998;317:703-713.
60. Adler A, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000; 321:412-419.
61. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med. 2008;359:1616-1620.
62. Moravski CJ, Skinner SL, Stubbs AJ, et al. The renin-angiotensin system influences ocular endothelial cell proliferation in diabetes: transgenic and interventional studies. Am J Pathol. 2003;162:151-160.
63. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998;351: 28-31.
64. Sjølie AK, Klein R, Porta M, et al; DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372:1385-1393.
65. American Medical Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33 (Suppl 1):S11-S61.
66. Klein BE, Moss SE, Klein R, Surawicz TS. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy hard exudate. Ophthalmology. 1991;98: 1261-1265.
67. Miljanovic B, Glynn RJ, Nathan DM, Manson JE, Schaumberg DA. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes. 2004;5:2883-2892.
68. Keech AC, Mitchell P, Summanen PA, et al; FIELD Study Investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet. 2007;370:1687-1697.
69. Meissner M, Stein M, Urbich C, et al. PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. Circ Res. 2004;94:324-332.
70. Tatti P, Arrigoni F, Longobardi A, Costanza F, di Blasi P, Merante D. Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus. Clin Drug Invest. 2008;28: 327-332.
71. Poster presentation. ESPEN 2010, Nice, 2010 Oct 2-5.